MARKET WIREYahoo Finance • 23h ago
Veracyte (VCYT) Stock Still Looks Cheap As Its 107% Run ContinuesYahoo Finance report covering Veracyte Inc. (VCYT) market action, institutional positioning, and fundamental catalysts.
Why VCYT Stock dropped -2.02% Today — RQD Quant Desk Flash
$49.00 -2.02% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $48.94
Veracyte Inc. (VCYT) earns a Roarable Rating of B (Buy) with 73/100 RQD Confidence. High-quality cash engine (70.1% gross margin, 5% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.
ROARABLE B • BUY
Cap $4.02B
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on VCYT Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is VCYT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, Veracyte Inc. (NASDAQ: VCYT) is rated B (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 73/100 at a spot price of $49.00 (-2.02% 1D, market cap $4.02B). Pillar breakdown: Fundamental Cash Engine 14/20, Institutional 13F & Options Flow 16/20, SEC Balance-Sheet Forensics 18/20, FRED Macro Regime Fit 14/20, and Executive Insider Alignment 11/20. Across 1015 tracked Health Care issuers, VCYT ranks #49 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does VCYT compare to CDNA and CELC in the Health Care sector?
▼
Within the Health Care sector (Medical Specialities), VCYT carries a Roarable B (73/100 RQD), trailing P/E of 63.2x, gross margin of 70.1%, and ROIC of 4.6%. By comparison, CDNA (CareDx Inc.) holds a B- grade (71/100 RQD, P/E N/A, ROIC -8.2%, cap $4.59B) and CELC (Celcuity Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $3.38B). Among the 5-stock peer group, CON leads on earnings multiple (31.6x) while CON leads on capital efficiency (19.7% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for VCYT?
▼
Per VCYT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001384101), Veracyte Inc. generated $517.1M in revenue (+16.0% YoY), $66.4M in net income, and $126.6M in free cash flow against $1.41B in total assets and $43.4M in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Priced at 63x earnings—high expectations leave less room for a lukewarm quarter. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $48.94 (-0.12%)🧬 Cannibal Buyback (-0.96% YoY Shares)⚙️ Cash Engine: 14/20 (B-) • 24.5% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record: Scores of 73/100 (B) historically ranked in the Top 13% of excess returns over the next 90 days (+7.1% avg 90D alpha vs SPY • 69.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERBUY • B
3-of-3 JEV AI Jury Bullish
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw C+ · Rk B+
Each axis scored 0–20
12M PRICE TARGET CONE+6.8% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for VCYT)Realized 20D OHLCV Swing Band: ±10.6%
Deterministic 5-Pillar Attribution (73/100 Composite)
🔍 WHY VCYT SCORES 73/100 (B) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+18/20 pts (25% of score)
Altman Z-Score 26.00 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 9/9
▲ #2 Bullish Driver: Whale & Options Positioning+16/20 pts (22% of score)
20D Institutional Volume Accumulation (±10.6% realized swing band)
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution11/20 pts (-9 pt drag)
Cannibal Buyback (-0.96% YoY Shares) & executive Form 4 sales trim 9 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade C+$43.51+6.2% Next Q
65
Q2 (-2Q)Grade B-$46.22+8.8% Next Q
68
Q3 (-1Q)Grade B$50.31-2.6% Next Q
70
CurrentGrade B$49.00+7.1% Hist 90D α
73
Trajectory: C+ (65) → B (73)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER
⚔️ Adversarial Opposing Case: Why the VCYT Bull Thesis Could Fail
Even with a 73/100 (B) score, VCYT faces multiple-compression risk if 63.2x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
⚠️ Forensic Kill-Switch #1
Priced at 63x earnings—high expectations leave less room for a lukewarm quarter.
⚠️ Forensic Kill-Switch #2
Dilution & Margin Drag: Cannibal Buyback (-0.96% YoY Shares) — any gross margin slip below 67.6% triggers an automatic RQD downgrade.
⚠️ Forensic Kill-Switch #3
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($44.95) or 200D SMA ($42.97) invalidates the momentum regime and cuts Target Base ($52.31) toward Bear Floor ($40.18).
🎲 LIVE PREDICTION MARKET ODDS TIED TO $VCYT• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “VCYT Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why VCYT Stock dropped -2.02% Today — RQD Quant Desk Flash
Veracyte Inc. (VCYT) dropped -2.02% to $49.00, trading at 62% of its 52-week range ($29.45 – $60.91). High-quality cash engine (70.1% gross margin, 5% return on capital) with steady institutional support.
- ▸Technical Tape: Trading at 62% of its 52-week range ($29.45 – $60.91) with RSI-14 at 57.7 (BULLISH MOMENTUM).
- ▸Volatility Profile: Historical 20-day realized swing band of ±10.6% around $49.00 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable B (Buy) backed by 70.1% gross margin and $126.6M annual free cash flow.
Live VCYT Headlines & Catalysts
MARKET WIRESimply Wall St • 1d ago
Veracyte (Nasdaq:VCYT) - Stock AnalysisSimply Wall St report covering Veracyte Inc. (VCYT) market action, institutional positioning, and fundamental catalysts.
CATALYSTYahoo Finance • 1d ago
Veracyte (VCYT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?Yahoo Finance report covering Veracyte Inc. (VCYT) market action, institutional positioning, and fundamental catalysts.
CATALYSTSeeking Alpha • 1d ago
Veracyte: Strong Diagnostic Growth And Improving Margins (NASDAQ:VCYT)Seeking Alpha report covering Veracyte Inc. (VCYT) market action, institutional positioning, and fundamental catalysts.
MARKET WIREGuruFocus • 1d ago
Veracyte Inc (VCYT) Stock Up 3.2% but GF Value Says Overvalued -- GF Score: 80/100GuruFocus report covering Veracyte Inc. (VCYT) market action, institutional positioning, and fundamental catalysts.
MARKET WIREInvesting.com Nigeria • 1d ago
Cathie Wood’s ARK sells Teradyne stock, buys Veracyte By Investing.comInvesting.com Nigeria report covering Veracyte Inc. (VCYT) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Titan • 1d ago
A director sold 1,864 Veracyte (VCYT) shares at $43.70 each under a trading plan.Stock Titan report covering Veracyte Inc. (VCYT) market action, institutional positioning, and fundamental catalysts.
CATALYSTYahoo Finance • 1d ago
Will Veracyte (VCYT) Beat Estimates Again in Its Next Earnings Report?Yahoo Finance report covering Veracyte Inc. (VCYT) market action, institutional positioning, and fundamental catalysts.
CATALYSTYahoo • 4d ago
4 Medical Stocks With a Healthy Shot at Q3 Earnings BeatsVTRS, RVTY, ELAN and VCYT have earnings beat signals ahead of Q3 results. Can drug launches, lab spending and cancer tests overcome margin pressures?
MARKET WIREYahoo • 4d ago
Veracyte to Participate in Upcoming Investor ConferencesSOUTH SAN FRANCISCO, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced it will be participating in the following investor conferences: UBS Glob
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk
Scheduled RQD Strong Buys & Whale Accumulation Briefing (VCYT Tape Review)
- ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
- ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
- ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
VCYT // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +46.49%▼ DESCENDING CHANNEL
2026-11-03O $52.17H $52.17L $49.00C $49.00VOL 1.02M
RES: $51.93SUP: $33.13SMA50: $44.95SMA200: $42.97
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
VCYT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle
42.9%/yr Implied 5Y Growth
vs. +16.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger
No active Ellis Vennor swing setup published on VCYT today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for VCYT. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for VCYT today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (VCYT)
Health Care Rank #49 of 1015
⚔️ CDNA vs VCYT Full Matrix →
1. Head-to-Head Health Care Peer Comparison (VCYT vs. CDNA, CELC, CON, BLLN)
Industry: Medical Specialities (41 Tracked Issuers)Across 1015 tracked Health Care securities in the Roarable RQD universe, Veracyte Inc. (VCYT) ranks #49 by composite RQD confidence (73/100, grade B) and #181 by equity capitalization ($4.02B). Within this direct 5-issuer industry benchmark cohort, CON leads on earnings valuation at 31.6x trailing P/E, while CON leads on capital efficiency and profitability with 19.7% ROIC and — gross margin. VCYT currently leads its immediate peer cohort in composite quantitative strength at 73/100 (B).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| VCYT
ACTIVE
Veracyte Inc. | B | 73/100 | 63.2x | 70.1% | 4.6% | -2.02% | $4.02B | Benchmark Subject |
| CDNA CareDx Inc. | B- | 71/100 | — | — | -8.2% | -1.75% | $4.59B | /cdna-vs-vcyt → |
| CELC Celcuity Inc. | E | 31/100 | — | — | -35.0% | -2.98% | $3.38B | /celc-vs-vcyt → |
| CON Concentra Group Holdings Parent Inc. | C+ | 68/100 | 31.6x | — | 19.7% | -0.12% | $5.15B | /con-vs-vcyt → |
| BLLN BillionToOne Inc. | B- | 70/100 | — | 68.3% | 2.9% | -2.57% | $5.35B | /blln-vs-vcyt → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001384101 ↗In its most recent audited fiscal period (FY2025, filed 2025-12-31), Veracyte Inc. (VCYT) reported GAAP revenue of $517.1M (+16.0% vs. FY2024 revenue of $445.8M , and +43.2% cumulative change since FY2023) , GAAP net income of $66.4M, operating cash flow of $136.3M, and free cash flow of $126.6M (+98.5% YoY). On the balance sheet, VCYT closed FY2025 with $1.41B in total assets against $43.4M in total debt (Altman Z-Score: 26.00, Piotroski F-Score: 9/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $517.1M | $66.4M | $136.3M | $126.6M | $1.41B | $43.4M |
| FY2024 (FY) | 2024-12-31 | $445.8M | $24.1M | $75.1M | $63.8M | $1.30B | $55.8M |
| FY2023 (FY) | 2023-12-31 | $361.1M | -$74.4M | $44.2M | $28.0M | $2.31B | $539.8M |
3. VCYT Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs VCYT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, Veracyte Inc. (NASDAQ: VCYT) is rated B (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 73/100 at a spot price of $49.00 (-2.02% 1D, market cap $4.02B). Pillar breakdown: Fundamental Cash Engine 14/20, Institutional 13F & Options Flow 16/20, SEC Balance-Sheet Forensics 18/20, FRED Macro Regime Fit 14/20, and Executive Insider Alignment 11/20. Across 1015 tracked Health Care issuers, VCYT ranks #49 in composite RQD confidence.
How does VCYT compare to CDNA and CELC in the Health Care sector?
Within the Health Care sector (Medical Specialities), VCYT carries a Roarable B (73/100 RQD), trailing P/E of 63.2x, gross margin of 70.1%, and ROIC of 4.6%. By comparison, CDNA (CareDx Inc.) holds a B- grade (71/100 RQD, P/E N/A, ROIC -8.2%, cap $4.59B) and CELC (Celcuity Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $3.38B). Among the 5-stock peer group, CON leads on earnings multiple (31.6x) while CON leads on capital efficiency (19.7% ROIC).
What are the biggest fundamental strengths and SEC risk factors for VCYT?
Per VCYT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001384101), Veracyte Inc. generated $517.1M in revenue (+16.0% YoY), $66.4M in net income, and $126.6M in free cash flow against $1.41B in total assets and $43.4M in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Priced at 63x earnings—high expectations leave less room for a lukewarm quarter. Institutional options positioning shows a 50% call / 50% put premium split.
Where is VCYT trading relative to its 50-day, 200-day, and 52-week technical levels?
VCYT last traded at $49.00 (-2.02% on volume of 1,150,365 shares), positioning the stock +9.01% above its 50-day simple moving average ($44.95) and +14.03% above its 200-day simple moving average ($42.97). Across its 52-week range of $29.45 to $60.91, VCYT sits at the 62.1% percentile with a 14-day RSI of 57.7 (BULLISH MOMENTUM) and an implied next-earnings move of ±10.6% ($43.81 to $54.19).
ROARABLE RATING BRIEF • RQD 73/100 (B)
✓ SEC XBRL & RQD VERIFIED
VCYT — Veracyte Inc.: What the Facts Mean to a Prospective Investor
Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31
1. Roarable Rating Brief: What This Means to a Prospective Investor
Veracyte Inc. (VCYT) earns a live Roarable RQD composite score of 73/100, corresponding to a B letter grade (Roarable Buy) at a spot price of $49.00 (-2.02% 1D, market capitalization $4.02B).
- Fundamental Cash Engine (14/20): Anchored by return on invested capital (ROIC) of 4.6%, gross margin of 70.1%, operating margin of 11.2%, and free cash flow yield of 3.02%.
- Whale 13F & Options Flow (16/20) + Insider Conviction (11/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
- Macro Regime Fit (14/20) + Forensic Balance Sheet (18/20): Incorporates a 1.08x equity beta, Altman Z-Score of 26.00, Piotroski F-Score of 9/9, and Debt/Equity of 0.03x.
2. Business Model, Unit Margins & SEC Financial Trajectory
Veracyte Inc. (VCYT) is a NASDAQ-listed issuer in the Health Care sector, Medical Specialities industry..2B.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Veracyte Inc. (VCYT) reported $517.1M in annual revenue (up from $445.8M in FY2024, +16.0% YoY) and $66.4M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($361.1M revenue, -$74.4M net income) through FY2025, VCYT scaled operating cash flow to $136.3M and free cash flow to $126.6M, backed by $1.41B in total assets against $43.4M in total debt.
3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff
- 🐂 Primary Bull Case (B • RQD 73/100): Big institutional funds and options desks are actively positioning on the bullish side. Clean SEC annual filing review with no major hidden accounting time-bombs. With Fundamental Cash Engine at 14/20 and Institutional Whale Flow at 16/20, sustained execution supports upside toward the upper end of the $29.45 – $60.91 52-week range.
- 🐻 Primary Bear Case & Valuation Risk: Priced at 63x earnings—high expectations leave less room for a lukewarm quarter. Investors must weigh 63.2x trailing P/E and 58.7x EV/EBITDA against 11.2% operating margins and a 1.08x macro beta.
4. 2nd-Order Butterfly Ripples & Key Questions to Watch
Operating in Medical Specialities (Health Care), VCYT carries a macro regime beta of 1.08 and gross margin of 70.1%.
- Key Question #1: Can VCYT sustain or expand its 11.2% operating margin and 4.6% ROIC against Medical Specialities peers over the next 4 quarters?
- Key Question #2: Following FY2025 revenue of $517.1M and free cash flow of $126.6M, how will capital allocation balance growth reinvestment against $43.4M in total debt?
- Key Question #3: How sensitive is VCYT's 53.1x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.08x)?
VCYT Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Veracyte Inc. (VCYT) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Yahoo Finance • 23h ago
Veracyte (VCYT) Stock Still Looks Cheap As Its 107% Run Continues Yahoo Finance report covering Veracyte Inc. (VCYT) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Simply Wall St • 1d ago
Veracyte (Nasdaq:VCYT) - Stock Analysis Simply Wall St report covering Veracyte Inc. (VCYT) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST Yahoo Finance • 1d ago
Veracyte (VCYT) Expected to Beat Earnings Estimates: Can the Stock Move Higher? Yahoo Finance report covering Veracyte Inc. (VCYT) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST Seeking Alpha • 1d ago
Veracyte: Strong Diagnostic Growth And Improving Margins (NASDAQ:VCYT) Seeking Alpha report covering Veracyte Inc. (VCYT) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE GuruFocus • 1d ago
Veracyte Inc (VCYT) Stock Up 3.2% but GF Value Says Overvalued -- GF Score: 80/100 GuruFocus report covering Veracyte Inc. (VCYT) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Investing.com Nigeria • 1d ago
Cathie Wood’s ARK sells Teradyne stock, buys Veracyte By Investing.com Investing.com Nigeria report covering Veracyte Inc. (VCYT) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 1d ago
A director sold 1,864 Veracyte (VCYT) shares at $43.70 each under a trading plan. Stock Titan report covering Veracyte Inc. (VCYT) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST Yahoo Finance • 1d ago
Will Veracyte (VCYT) Beat Estimates Again in Its Next Earnings Report? Yahoo Finance report covering Veracyte Inc. (VCYT) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
VCYT Bull vs. Bear Conversation Board — What's Your Call at $49.00?
🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON VCYT 🐻 33% BEARISH CONVICTION
SI SiliconVal_Bull RQD DEBATE OPENER • Growth & Tech Investor 🐂 BULLISH
🎯 Target: $63.51 (+27.0%)
📌 Pinned Debate Forensic balance sheet is strong (Altman Z 26, Piotroski F 9/9, Debt/Equity 0.03) and debt fell from $539.8M to $43.4M over FY 2023–FY
Forensic balance sheet is strong (Altman Z 26, Piotroski F 9/9, Debt/Equity 0.03) and debt fell from $539.8M to $43.4M over FY 2023–FY 2025.. When you look under the hood at VCYT, Fundamental Cash Engine is 14/20 with 70.1% gross margins and 4.6% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (16/20) has been quietly accumulating below $60.91. My 12M target is $63.51.
EarningsSniper 🐂 BULL
@ShortSeller_Dan Shorting a 16/20 institutional whale-flow stock at $50.01 is dangerous when funds are rotating into Health Care.
SH ShortSeller_Dan RQD DEBATE OPENER • Forensic Short Bias 🐻 BEARISH
🎯 Target: $37.51 (-25.0%)
Spot @ $50.01 Valuation is demanding at 63.2 P/E (TTM) and 58.7 EV/EBITDA against a 4.6% ROIC and weak insider-conviction pillar (11/20).
Careful chasing VCYT at $50.01. Valuation is demanding at 63.2 P/E (TTM) and 58.7 EV/EBITDA against a 4.6% ROIC and weak insider-conviction pillar (11/20).. Gross margin is 70.1%, but operating margin is 11.2%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $37.51 on multiple compression.